No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki

The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using dat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Toriyama, Eo, Hata, Tomoko, Yokota, Ken‐ichi, Chiwata, Masahiko, Kamijo, Rena, Hashimoto, Miki, Taguchi, Masataka, Horai, Makiko, Matsuo, Masatoshi, Matsuo, Emi, Takasaki, Yumi, Kawaguchi, Yasuhisa, Itonaga, Hidehiro, Sato, Shinya, Ando, Koji, Sawayama, Yasushi, Taguchi, Jun, Imaizumi, Yoshitaka, Tsushima, Hideki, Jo, Tatsuro, Yoshida, Shinichiro, Moriuchi, Yukiyoshi, Miyazaki, Yasushi
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7734160/
https://ncbi.nlm.nih.gov/pubmed/32939867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14653
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars